Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT04427787
Title A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NET (LOLA)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

large cell neuroendocrine carcinoma

neuroendocrine tumor

pancreatic endocrine carcinoma

rectum neuroendocrine neoplasm

small intestine neuroendocrine neoplasm

pulmonary neuroendocrine tumor

gastrointestinal neuroendocrine tumor


Cabozantinib + Lanreotide acetate

Age Groups: adult | senior
Covered Countries ITA

No variant requirements are available.